Sign In
Buy CLVLY
Clinuvel Pharmaceuticals Earnings Calls
| Release date | Feb 25, 2026 |
| EPS estimate | $0.198 |
| EPS actual | $0.147 |
| EPS Surprise | -25.90% |
| Revenue estimate | 25.664M |
| Revenue actual | 26.219M |
| Revenue Surprise | 2.16% |
| Release date | Aug 21, 2025 |
| EPS estimate | $0.182 |
| EPS actual | $0.286 |
| EPS Surprise | 57.37% |
| Revenue estimate | 40.033M |
| Revenue actual | 38.779M |
| Revenue Surprise | -3.13% |
| Release date | Feb 26, 2025 |
| EPS estimate | $0.136 |
| EPS actual | $0.173 |
| EPS Surprise | 27.15% |
| Revenue estimate | 21.618M |
| Revenue actual | 22.064M |
| Revenue Surprise | 2.06% |
| Release date | Aug 28, 2024 |
| EPS estimate | $0.296 |
| EPS actual | $0.326 |
| EPS Surprise | 10.42% |
| Revenue estimate | 36.592M |
| Revenue actual | 36.923M |
| Revenue Surprise | 0.90% |
Last 4 Quarters for Clinuvel Pharmaceuticals
Below you can see how CLVLY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 28, 2024 |
| Price on release | $9.43 |
| EPS estimate | $0.296 |
| EPS actual | $0.326 |
| EPS surprise | 10.42% |
| Date | Price |
|---|---|
| Aug 22, 2024 | $8.94 |
| Aug 23, 2024 | $9.25 |
| Aug 26, 2024 | $9.25 |
| Aug 27, 2024 | $9.24 |
| Aug 28, 2024 | $9.43 |
| Aug 29, 2024 | $10.33 |
| Aug 30, 2024 | $10.30 |
| Sep 03, 2024 | $10.03 |
| Sep 04, 2024 | $10.03 |
| 4 days before | 5.48% |
| 4 days after | 6.36% |
| On release day | 9.54% |
| Change in period | 12.19% |
| Release date | Feb 26, 2025 |
| Price on release | $7.17 |
| EPS estimate | $0.136 |
| EPS actual | $0.173 |
| EPS surprise | 27.15% |
| Date | Price |
|---|---|
| Feb 20, 2025 | $7.20 |
| Feb 21, 2025 | $7.15 |
| Feb 24, 2025 | $7.42 |
| Feb 25, 2025 | $7.12 |
| Feb 26, 2025 | $7.17 |
| Feb 27, 2025 | $7.50 |
| Feb 28, 2025 | $7.12 |
| Mar 03, 2025 | $7.34 |
| Mar 04, 2025 | $7.70 |
| 4 days before | -0.417% |
| 4 days after | 7.39% |
| On release day | 3.42% |
| Change in period | 6.94% |
| Release date | Aug 21, 2025 |
| Price on release | $7.82 |
| EPS estimate | $0.182 |
| EPS actual | $0.286 |
| EPS surprise | 57.37% |
| Date | Price |
|---|---|
| Aug 15, 2025 | $8.53 |
| Aug 18, 2025 | $7.44 |
| Aug 19, 2025 | $7.80 |
| Aug 20, 2025 | $7.58 |
| Aug 21, 2025 | $7.82 |
| Aug 22, 2025 | $8.25 |
| Aug 25, 2025 | $8.26 |
| Aug 26, 2025 | $8.57 |
| Aug 27, 2025 | $8.76 |
| 4 days before | -8.32% |
| 4 days after | 11.99% |
| On release day | 5.50% |
| Change in period | 2.67% |
| Release date | Feb 25, 2026 |
| Price on release | $8.24 |
| EPS estimate | $0.198 |
| EPS actual | $0.147 |
| EPS surprise | -25.90% |
| Date | Price |
|---|---|
| Feb 19, 2026 | $8.06 |
| Feb 20, 2026 | $8.47 |
| Feb 23, 2026 | $8.52 |
| Feb 24, 2026 | $8.44 |
| Feb 25, 2026 | $8.24 |
| Feb 26, 2026 | $7.88 |
| Feb 27, 2026 | $7.56 |
| Mar 02, 2026 | $7.42 |
| Mar 03, 2026 | $7.29 |
| 4 days before | 2.23% |
| 4 days after | -11.53% |
| On release day | -4.43% |
| Change in period | -9.55% |
Clinuvel Pharmaceuticals Earnings Call Transcript Summary of Q4 2025
CLINUVEL delivered a strong FY2025 with revenues up 10% to $105M, marking a ninth consecutive annual profit and an eighth consecutive dividend (the fourth fully franked). The group remains debt-free with cash reserves up ~22% (~$40M increase), providing 3–4 years of operational runway and strategic optionality. Management is actively reinvesting in growth: personnel (+31%), R&D (≈20% of revenue / 40% of expenditure), and communications/brand-building (CBM up 100%). Key operational highlights: CUV105 (vitiligo) Phase III is fully recruited with a first readout expected H2 2026; preparation of CUV107 is underway; expansion of EPP commercial footprint continues (104 trained sites in North America, targeting 120); ACTH generic (NEURACTHEL) manufacturing/DMF work is nearing completion; photocosmetics development is in advanced safety/toxicology stages with INCI/CAS work ongoing. Management signals a medium-term expenditure plateau target of roughly $50–55M p.a., and they continue to evaluate revenue diversification, vertical integration, and selective M&A while pursuing a Level 1→Level 2 ADR / 8% U.S. listing upgrade. Regulators to watch: Health Canada outcome for SCENESSE and ongoing regulatory dialogues in vitiligo (FDA/EMA interactions planned).
